Amneal Pharmaceuticals, Inc. (AMRX)
Healthcare
Drug Manufacturers - Specialty & Generic
18.30 $
-1.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Amneal Pharmaceuticals, Inc. (AMRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 3,776 million $. Tick rows to compare them in a chart.
| Tick rows to compare them in a chart (up to 4) | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3,687 | 3,473 | 3,456 | 3,510 | 3,461 | 3,501 | 3,365 | 3,423 | 3,600 | 3,678 | 3,540 | 3,776 | |
| 1,456 | 1,378 | 1,380 | 1,485 | 1,513 | 1,588 | 1,510 | 1,585 | 1,838 | 1,911 | 1,798 | 1,947 | |
| 87 | 92 | 48 | 44 | 74 | 111 | 59 | 81 | 201 | 311 | 198 | 128 | |
| 92 | 94 | 48 | 47 | 74 | 112 | 59 | 81 | 201 | 311 | 198 | 128 | |
| 691 | 646 | 704 | 803 | 786 | 776 | 800 | 849 | 924 | 940 | 903 | 1,021 | |
| 576 | 581 | 571 | 576 | 596 | 612 | 601 | 609 | 615 | 606 | 642 | 678 | |
| 599 | 599 | 599 | 599 | 598 | 597 | 597 | 597 | 596 | 595 | 594 | 593 | |
| 983 | 890 | 859 | 820 | 780 | 732 | 689 | 650 | 588 | 563 | 535 | 588 | |
| 3,496 | 3,411 | 3,473 | 3,514 | 3,495 | 3,546 | 3,425 | 3,470 | 3,710 | 3,672 | 3,586 | 3,659 | |
| 761 | 847 | 834 | 1,114 | 1,095 | 1,130 | 1,076 | 1,107 | 862 | 882 | 728 | 883 | |
| 123 | 228 | 229 | 452 | 381 | 340 | 338 | 335 | 21 | 22 | 21 | 121 | |
| 177 | 144 | 175 | 200 | 235 | 260 | 193 | 667 | 266 | 255 | 228 | 721 | |
| 2,583 | 2,427 | 2,420 | 2,178 | 2,170 | 2,162 | 2,154 | 2,146 | 2,567 | 2,565 | 2,566 | – | |
| 331 | 20 | -64 | -57 | -93 | -109 | -132 | -113 | -109 | -71 | -45 | 33 | |
| -392 | -490 | -582 | -576 | -576 | -607 | -595 | -572 | -570 | -535 | -473 | – | |
| 160 | 244 | 307 | 319 | 310 | 310 | 324 | 322 | 325 | 325 | 329 | 328 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.